- Home
- IOVA vs ORIC Comparison
IOVA vs ORIC Comparison
Compare IOVA & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IOVA
- ORIC
- Stock Information
- Founded
- IOVA 2007
- ORIC 2014
- Country
- IOVA United States
- ORIC United States
- Employees
- IOVA N/A
- ORIC N/A
- Industry
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- IOVA Health Care
- ORIC Health Care
- Exchange
- IOVA Nasdaq
- ORIC Nasdaq
- Market Cap
- IOVA 975.1M
- ORIC 938.2M
- IPO Year
- IOVA N/A
- ORIC 2020
- Fundamental
- Price
- IOVA $2.69
- ORIC $9.74
- Analyst Decision
- IOVA Buy
- ORIC Strong Buy
- Analyst Count
- IOVA 11
- ORIC 9
- Target Price
- IOVA $11.90
- ORIC $17.25
- AVG Volume (30 Days)
- IOVA 16.7M
- ORIC 1.3M
- Earning Date
- IOVA 08-07-2025
- ORIC 08-12-2025
- Dividend Yield
- IOVA N/A
- ORIC N/A
- EPS Growth
- IOVA N/A
- ORIC N/A
- EPS
- IOVA N/A
- ORIC N/A
- Revenue
- IOVA $241,525,000.00
- ORIC N/A
- Revenue This Year
- IOVA $86.62
- ORIC N/A
- Revenue Next Year
- IOVA $69.13
- ORIC N/A
- P/E Ratio
- IOVA N/A
- ORIC N/A
- Revenue Growth
- IOVA 636.99
- ORIC N/A
- 52 Week Low
- IOVA $1.64
- ORIC $3.90
- 52 Week High
- IOVA $12.51
- ORIC $14.67
- Technical
- Relative Strength Index (RSI)
- IOVA 54.92
- ORIC 46.26
- Support Level
- IOVA $2.44
- ORIC $9.32
- Resistance Level
- IOVA $2.85
- ORIC $10.06
- Average True Range (ATR)
- IOVA 0.24
- ORIC 0.48
- MACD
- IOVA -0.00
- ORIC -0.02
- Stochastic Oscillator
- IOVA 83.16
- ORIC 57.46
About IOVA Iovance Biotherapeutics Inc.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533. The Company has as one operating segment, focused on the discovery and development of therapies designed to counter the resistance mechanisms in cancer.